NL-OMON37035已完成不适用
Reversal of oral direct factor Xa inhibitors rivaroxaban and apixaban by two different dosages of prothrombin complex concentrate (Cofact®) - Reversal of novel oral anticoagulants by prothrombin complex concentrate
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •* Healthy male subjects as documented by laboratory screen tests (including HIV/HBV/HCV screening), personal medical history and normal physical examination.
- •* Age *18 years, < 50 years.
- •* No personal history of thrombotic disease/bleeding disorders.
- •* No significant family history of thrombotic disease/bleeding disorders, such as recurrent thrombotic/bleeding events or thrombotic/bleeding events in the absence of any risk factors.
- •* Able to provide written informed consent.
排除标准
- •Exclusion criteria are:
- •* History of allergic reaction to blood products.
- •* Current participation in any other investigational drug study or within the past 30 days.
- •* Presence of any condition that, as judged by the investigator, would place the subject at increased risk of harm if he participated in the study.
研究者
相似试验
已完成
3 期
The effect of oral rivaroxaban in treating and in the long term prevention in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism.Pulmonary embolismDeep vein thrombosisCardiovascular - Diseases of the vasculature and circulation including the lymphatic systemACTRN12607000222448Bayer Australia Limited5,193
进行中（未招募）
不适用
Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism.Treatment and secondary prevention of venous thromboembolism in patients with acute symptomatic deep- vein thrombosis or pulmonary embolismEUCTR2006-004495-13-DEBayer Healthcare AG7,465
进行中（未招募）
不适用
Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism.Treatment and secondary prevention of venous thromboembolism in patients with acute symptomatic deep- vein thrombosis or pulmonary embolismEUCTR2006-004495-13-FIBayer Healthcare AG7,400
已完成
3 期
Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep-Vein Thrombosis or Pulmonary EmbolismCTRI/2007/091/000024Bayer Healthcare AG
进行中（未招募）
不适用
Oral direct factor Xa inhibitor rivaroxaban in patients with acute symptomatic deep-vein thrombosis or pulmonary embolism.EUCTR2006-004495-13-IEBayer Healthcare AG7,465